SDY vs XBI
SPDR S&P Dividend ETF vs SPDR S&P Biotech ETF
- • SDY pays a higher dividend yield (2.45%).
Side-by-side metrics
| Metric | SDY | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.45% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $21.39B | $10.73B |
YTD return | 11.73% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.58 | 1.10 |
P/E ratio | 20.86 | — |
Last price | $153.64 | $164.01 |
Inception | — | — |
Issuer | State Street | State Street |
SDY top holdings
| VZ | Verizon Communications Inc | 2.14% |
| O | Realty Income Corp | 2.13% |
| KVUE | Kenvue Inc | 1.75% |
| KMB | Kimberly-Clark Corp | 1.75% |
| ABBV | AbbVie Inc | 1.62% |
| QCOM | Qualcomm Inc | 1.56% |
| TXN | Texas Instruments Inc | 1.55% |
| TGT | Target Corp | 1.54% |
| ADP | Automatic Data Processing Inc | 1.53% |
| EIX | Edison International | 1.44% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About SDY
SDY (SPDR S&P Dividend ETF) is Highest-yielding S&P Composite 1500 dividend growers. Managed by State Street, the fund carries $21.4B in assets under management, an expense ratio of 0.35%, a dividend yield of 2.45%. Its largest holding is Verizon Communications Inc (VZ), which represents 2.1% of the portfolio. Real Estate is the fund's largest sector exposure at 4.4%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.